Please login to the form below

Not currently logged in
Email:
Password:

CAR therapies

This page shows the latest CAR therapies news and features for those working in and with pharma, biotech and healthcare.

FDA approves Roche’s Actemra COVID-19 trial

FDA approves Roche’s Actemra COVID-19 trial

It was first cleared by the FDA as a treatment for rheumatoid arthritis and has also subsequently been approved in juvenile idiopathic arthritis, giant cell arteritis and CRS associated with ... T cell therapies for cancer.

Latest news

More from news
Approximately 1 fully matching, plus 86 partially matching documents found.

Latest Intelligence

  • The impact of COVID-19 on clinical trials The impact of COVID-19 on clinical trials

    impact on the initiation and completion of hundreds of clinical trials involving investigational therapies for many serious diseases. ... Therapy mechanism of action – immunosuppressive therapies and therapies that require complex and prolonged

  • Cortellis Drugs to Watch in 2020 report Cortellis Drugs to Watch in 2020 report

    Thanks to the CAR construct, the engineered T cells can recognise and attack the CD19-expressing cancer cells. ... This composition could confer efficacy and safety advantages, including fewer adverse effects such as cytokine release syndrome (CRS) and

  • China’s homecoming heroes fuel a biotech boom with rapid CAR-T advances China’s homecoming heroes fuel a biotech boom with rapid CAR-T advances

    At the spear point is China’s emergence as the epicentre of biotech research and development, with its performance on CAR-T therapies turning heads. ... We are introducing the international best practices of developing CAR T to our China team and

  • European biotech: a new generation of leaders emerges European biotech: a new generation of leaders emerges

    year. The promise of the molecule is great, with analysts seeing it as a possible challenge to Novartis and Gilead’s CAR-T therapies. ... This means its clinical outcomes could match those seen in the CAR-Ts, but without the complexity and cost of

  • The dawn of a new era in medical education The dawn of a new era in medical education

    Innovation is not without its challenges. Let’s take haematology as our case study; there has been a flurry of revolutionary cell therapies to treat blood cancers, including CAR-T therapies. ... therapies, where the administration is not as simple as

More from intelligence
Approximately 0 fully matching, plus 27 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 6 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Streaming Well

Streaming Well is a healthcare-focused, award-winning video production company which operates in the US and Europe. We create engaging visual...

Latest intelligence

3 ways to increase patient retention rates in clinical trials
Retention rates are falling in clinical trials. Yes, it is a bit disheartening. But there are some straightforward things you can do to turn it around....
Kulveer Singh
Surviving cancer: a new era for patients
Now more than ever, a shift in perspective is needed...
Crisis? No problem!
Issues planning & management for pharma spokespeople, by Andrew Smith...

Infographics